Mason Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mason Lai has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- A. McGarry Houghton
Fred Hutchinson Cancer Center 9 , Seattle, Washington
6 shared publications - Diane Tseng
University of Washington, Seattle, Washington, USA
6 shared publications - Evan William Newell
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
6 shared publications - Jianhong Cao
Immune Monitoring Core, Fred Hutchinson Cancer Center, Seattle, Washington
6 shared publications - Koshlan Mayer-Blackwell
Fred Hutchinson Cancer Research Center
6 shared publications - Kyle Kristopher Payne
Rutgers Cancer Institute
6 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-13 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
Supplementary Tables 1-13 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-13 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
Supplementary Tables 1-13 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
Validation of TCR disease status prediction on a CMV cohort
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
Validation of TCR disease status prediction on a CMV cohort
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from T-cell Receptor Profiling of Blood to Detect Lung Cancer
The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from T-cell Receptor Profiling of Blood to Detect Lung Cancer
The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
TCRβ sequences belonging to both TILS-A and TILS-B classifiers
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
TCRβ sequences belonging to both TILS-A and TILS-B classifiers
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from T-cell Receptor Profiling of Blood to Detect Lung Cancer
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 13 (9) , 1405-1417
T-cell Receptor Profiling of Blood to Detect Lung Cancer
The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 13 (9) , 1405-1417
T-cell Receptor Profiling of Blood to Detect Lung Cancer
The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.